NCT02656797

Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Soroka University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.

Detailed description

Randomized, double blind, placebo controlled study. The study will include 108 patients with cutenous leishmaniasis of Leishmania species major and tropica, confired by Polymerase Chain Reaction of a sample from a lesion. Cure rate will be compared between patients treated with Amphotericin-B 0.4% Liposomal Gel and patients treated with placebo gel preparation.

Conditions

• Leishmaniasis

Interventions

Type	Name	Description
DRUG	Topical Amphotericin-B 0.4% liposomal gel	Topical Amphotericin-B 0.4% liposomal gel

Timeline

• Start date: 2018-01-30
• Primary completion: 2021-06-01
• Completion: 2021-10-01
• First posted: 2016-01-15
• Last updated: 2022-03-15

Locations

1 site across 1 country: Israel